Scilex (SCLX) said Wednesday that the US Food and Drug Administration has approved its request for orphan drug designation for colchicine as a treatment for pericarditis.
Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, the company said.
Shares of Scilex were down more than 11% in recent trading.
Price: 6.14, Change: -0.78, Percent Change: -11.27